Accelerated Tattoo Removal: A Review of the DeScribe PFD Patch

The direct answer

The DeScribe® PFD Patch is an FDA-cleared, single-use accessory device consisting of a transparent silicone patch infused with liquid perfluorodecalin (PFD). Its primary function is to resolve the epidermal gas "frosting" (whitening) that occurs immediately after a laser pulse strikes tattoo ink, allowing the provider to perform up to 4 laser passes in a single treatment session instead of the standard single pass.

During traditional laser tattoo removal, the intense light energy creates rapid thermal expansion, vaporizing water in the skin and forming microbubbles of steam and gas in the epidermis. This frosting layer acts as a highly reflective optical shield, scattering subsequent laser light and forcing clinicians to wait 20 to 25 minutes for the gas to naturally reabsorb before making another pass.

By placing the PFD-infused patch over the treatment area, the perfluorodecalin rapidly dissolves these gaseous microbubbles within seconds, restoring optical clarity to the skin. Clinical evidence demonstrates that this multi-pass technique accelerates ink clearance, can reduce the total number of office visits needed for complete removal, and provides a protective thermal barrier that minimizes epidermal injury, blistering, and post-procedure downtime.

To understand the broader context of complications, hyperpigmentation risks, and recovery guidelines, see our comprehensive guide on laser tattoo removal side effects, and for financial calculations and session estimates, review our tattoo removal cost guide.

---

The Physics of Optical Clearing: How PFD Works

To understand why the DeScribe Patch is clinically effective, one must examine the optical behavior of light passing through human skin during laser-tissue interactions.

The Problem: Epidermal Frosting and Light Scattering

Laser tattoo removal relies on the principle of selective photothermolysis. A high-power, short-pulse (nanosecond Q-switched or picosecond) laser emits a specific wavelength of light (e.g., 1064 nm or 755 nm) that is preferentially absorbed by the tattoo pigment. The absorption of this intense energy causes rapid heating of the ink particles, leading to photoacoustic shattering.

This violent energy transfer vaporizes intracellular water, generating microscopic steam and gas bubbles within the epidermis and upper dermis. Visibly, this appears as an immediate whitening of the skin, commonly referred to as epidermal frosting.

From an optical perspective, these gas bubbles create a severe refractive index mismatch. The refractive index of air/gas is 1.00, while the surrounding hydrated epidermal tissue has a refractive index of approximately 1.40. When the laser light strikes this boundary, the massive difference in refractive indices causes intense light scattering. The light bounces off the gas bubbles in all directions rather than traveling downward to reach the deeper layers of tattoo ink.

Standard Laser Pass (No Patch):
Laser Beam ──>  ▼  (strikes skin)
           [Epidermal Frosting / Gas Bubbles]  (Refractive Index = 1.00)
                 \   /   \   /
                  ▼  ▼   ▼  ▼  (Scattered Light - Cannot reach deep ink)

PFD Patch Laser Pass:
Laser Beam ──>  ▼  (passes through patch)
           [DeScribe PFD Patch & PFD Liquid]  (Refractive Index = 1.30 - 1.40)
                 │   │   │   │
                 ▼   ▼   ▼   ▼  (Direct Light - Penetrates to shatter deep ink)

Performing a second laser pass immediately over frosted skin is clinically useless and highly dangerous. The scattered light is absorbed superficially by epidermal melanin, significantly increasing the risk of thermal burns, blisters, and permanent pigmentary changes (hyper- or hypopigmentation), while failing to reach the target ink.

The Solution: Index Matching with Perfluorodecalin (PFD)

Perfluorodecalin ($C_{10}F_{18}$) is a synthetic fluorocarbon liquid that is highly biocompatible and has an exceptional capacity for dissolving gases, including carbon dioxide, oxygen, and water vapor.

The optical clearing mechanism of the DeScribe Patch relies on two properties:

1. Gas Dissolution: PFD rapidly dissolves the pocketed steam and carbon dioxide bubbles generated by the laser, collapsing the microbubbles and resolving the frosting effect in seconds. This occurs because the solubility of gases in perfluorocarbons is orders of magnitude higher than in water or blood.
2. Refractive Index Matching: PFD has a refractive index of approximately 1.30 to 1.31. The medical-grade silicone patch itself has a refractive index of approximately 1.40. When the patch is applied to the skin, the PFD liquid fills the microscopic gaps between the patch, the stratum corneum, and the epidermal structures. Because the refractive index of PFD (1.31) closely matches the refractive index of the silicone patch (1.40) and hydrated epidermal tissue (1.40), the optical boundary is smoothed. Light scattering is minimized, allowing the laser beam to penetrate directly through the patch and deep into the dermis to strike the remaining ink particles.

Why Ultrasound Gels and Water Fail

Practitioners sometimes ask why standard ultrasound gel or water cannot be used as an index-matching agent. While water has a refractive index of 1.33 and ultrasound gel is close to 1.35, neither substance possesses gas-dissolution properties.

If a provider attempts to laser through ultrasound gel, the gas bubbles generated by the first pulse remain trapped beneath the gel layer, continuing to scatter light. Ultrasound gel also lacks the thermal capacity and structural integrity of the medical-grade silicone patch, failing to protect the epidermis from accumulated heat during multiple passes.

Additionally, the silicone patch acts as a physical heat sink. It conducts excess thermal energy away from the epidermal surface, protecting the surrounding skin and reducing the pain associated with repeated laser passes.

---

FDA 510(k) Clearance Timeline and Indications

The regulatory history of the DeScribe PFD Patch demonstrates a step-by-step expansion of its cleared indications, tracking the evolution of laser technology from Q-switched to picosecond devices.

Initial FDA Clearance: K150212

The DeScribe Transparent PFD Patch was first cleared by the U.S. Food and Drug Administration on April 20, 2015 (510(k) decision date), under application K150212. The original clearance was submitted by On Light Sciences, Inc. (the device's developer).

Under K150212, the patch was classified as a class II accessory device under the product code PKO ("Transparent Patch For Use In Treatment Of Tattoos"). The initial clearance was narrow: it was indicated for use as an accessory to laser tattoo removal procedures using a 755 nm Q-switched Alexandrite laser in patients with Fitzpatrick Skin Types I-III. The clinical data submitted showed that the patch allowed for multiple passes during a single session without increasing adverse events.

Indication Expansion: K172689

On November 29, 2017, Merz North America, Inc. (which had acquired the rights to the device) received an expanded FDA clearance under application K172689. This clearance significantly expanded the list of compatible laser wavelengths, pulse widths, and target skin types:

1. Q-Switched Lasers: Approved for use with Q-switched lasers operating at wavelengths of 532 nm, 694 nm, 755 nm, and 1064 nm.
2. Picosecond Lasers: Approved for use with ultra-short pulse picosecond lasers operating at wavelengths of 532 nm, 755 nm, 785 nm, and 1064 nm.
3. Fitzpatrick Skin Types: Retained the primary indication for Fitzpatrick Skin Types I-III, while clinical experience was expanded to allow providers to use the patch on darker skin types under specific safety protocols.

According to the regulatory documents, the device remains indicated "as an accessory to laser tattoo removal procedures... to allow for multiple laser passes during a single treatment session." No other device currently holds clearances under the PKO product code, making the DeScribe Patch a unique regulatory entity in the laser accessory market.

---

Clinical Efficacy: Multi-Pass Protocols (R20 vs. PFD-Assisted)

Before the introduction of optical clearing agents, dermatologists and plastic surgeons attempted to speed up tattoo removal using the R20 Protocol.

Comparing the Protocols

The Classic R20 Protocol

First described in clinical literature in 2012, the R20 protocol calls for performing four separate laser passes over the tattoo during a single office visit, with a 20-minute wait time between each pass. The 20-minute interval is required to allow the epidermal gas frosting to naturally resolve so the skin becomes optically clear again.

While the R20 protocol demonstrated significantly faster tattoo clearance than the traditional single-pass method (clearing tattoos in fewer total months), it was highly impractical:

• Time Commitment: A single treatment session took over 80 minutes of office time, forcing the patient to remain in the clinic and tie up treatment rooms.
• Patient Discomfort: The cumulative trauma of four passes without epidermal protection led to high pain scores, severe swelling, and a high incidence of blistering and epidermal crusting.

The PFD-Assisted Multi-Pass Protocol

The PFD-assisted protocol replaces the 20-minute wait time with the instant clearing property of perfluorodecalin. The clinical workflow is straightforward:

1. The tattoo is cleansed, and a thin layer of PFD liquid or gel is applied to the skin.
2. The DeScribe silicone patch is placed over the PFD layer, ensuring complete contact without air bubbles.
3. The provider performs the first laser pass directly through the transparent patch.
4. As the laser fires, microbubbles form, but they dissolve within seconds under the PFD layer.
5. The provider performs a second, third, and fourth pass immediately, adjusting wavelengths or spot sizes as needed to target different ink depths and colors.
6. The entire 4-pass session is completed in under 5 minutes of laser time.

Published Clinical Evidence

Two key peer-reviewed studies, both published in Lasers in Surgery and Medicine, established the evidence base for the PFD patch.

The pilot study (Biesman, O'Neil, and Costner, 2015; PubMed 26266835) split tattoos in half: one half received a standard single-pass protocol and the other received a multi-pass protocol through the transparent PFD patch. In a majority of subjects, the patch-treated side showed more rapid tattoo clearance with higher patient and clinician satisfaction than conventional treatment, and the multi-pass sessions were well tolerated, with no severe adverse events.

A subsequent pivotal trial (Biesman and Costner; Lasers in Surgery and Medicine, DOI 10.1002/lsm.22659) expanded the comparison at scale and confirmed that treating through the patch enables multiple high-fluence passes in a single session with faster clearance than single-pass treatment. Across the published evidence, investigators report that multi-pass treatment through the patch is well tolerated, with reduced whitening and patient-preference for the patch side. A separate chart review (PubMed 30311666) specifically examined safety in Fitzpatrick skin types IV-VI, treating 14 patients with picosecond (532, 785, 1064 nm) and Q-switched Nd:YAG (1064 nm) lasers and reporting that the patch could be used safely in darker skin types with appropriate settings.

---

Clinical Workflow: A Step-by-Step Guide for Injectors and Laser Operators

To achieve optimal results while maintaining patient safety, laser operators should follow a standardized clinical workflow when incorporating the DeScribe Patch:

Phase 1: Patient Preparation

1. Cleanse the Target Site: Thoroughly clean the tattoo and surrounding skin with chlorhexidine or isopropyl alcohol. Ensure all topical creams, makeup, and debris are completely removed.
2. Apply Topical Anesthesia (Optional): If using a topical numbing cream (e.g., LMX4 or prescription BLT cream), apply it 30 to 45 minutes before the session under occlusion. Remove the cream completely and re-cleanse the skin before proceeding.
3. Prepare the Laser: Calibrate the laser settings (spot size, fluence, and pulse width) based on the ink colors, depth, and the patient's skin type. For the first pass, start with the longest appropriate wavelength (e.g., 1064 nm for black/dark ink).

Phase 2: Patch Application

1. Apply PFD Liquid/Gel: Dispense a generous layer of perfluorodecalin liquid or gel onto the tattoo. Ensure the entire area to be treated is covered with a thin, continuous film.
2. Position the Silicone Patch: Peel the protective backing off the DeScribe silicone patch. Place the patch gently over the PFD layer, working from the center outward to push out any trapped air bubbles. The patch must sit flat against the skin surface.
3. Ensure Optical Coupling: Verify that the tattoo is clearly visible through the transparent silicone patch. If air pockets remain, press them out using a sterile gauze pad.

Phase 3: Laser Execution

1. Perform Pass 1: Position the laser handpiece perpendicular to the patch surface. Deliver the laser pulses through the patch. You will notice immediate whitening (frosting) under the silicone.
2. Observe Optical Clearing: Wait 5 to 20 seconds. The epidermal frosting should resolve, rendering the ink visible again.
3. Perform Pass 2: Deliver the second laser pass. If targeting a different ink color (e.g., red/orange), switch the wavelength (e.g., to 532 nm) or adjust the spot size and fluence.
4. Perform Passes 3 and 4: Repeat the process for up to 4 passes. If the patch becomes dry, lift a corner slightly and add 2–3 drops of PFD liquid before replacing it and firing.

Phase 4: Post-Treatment Care

1. Remove the Patch: Gently peel the silicone patch off the skin and discard it.
2. Cleanse the Skin: Wipe away any residual PFD liquid using a sterile saline-soaked gauze.
3. Apply Post-Laser Ointment: Apply a thin layer of petrolatum, aquaphor, or a specialized post-procedure barrier gel.
4. Dress the Area: Cover the treated site with a non-adherent sterile dressing (e.g., Telfa pad) secured with medical tape. Instruct the patient on standard wound care, emphasizing sun protection and the avoidance of picking scabs.

---

Safety Profile and openFDA MAUDE Analysis

While the clinical literature supports the safety of the DeScribe Patch, a thorough clinical review requires analyzing post-market safety databases to identify potential real-world complications.

openFDA MAUDE Database Findings

The FDA’s Manufacturer and User Facility Device Experience (MAUDE) database monitors adverse events associated with medical devices. A query of the FDA MAUDE database under product code PKO (Transparent Patch For Use In Treatment Of Tattoos) yields 6 adverse event reports.

All 6 reports involve the manufacturer Merz North America, Inc., and are classified as Injury. A detailed inspection of these specific reports (including report numbers 3013840437-2022-00029 and 3013840437-2025-00065) reveals a consistent pattern of mild, localized complications:

• Transient Blistering: The most common theme in the narratives is the development of superficial blisters in the days following a multi-pass treatment. Blistering is a recognized side effect of laser tattoo removal (caused by thermal separation of the epidermal-dermal junction), and the reports typically describe standard post-laser blisters that resolved without scarring.
• Epidermal Peeling / Scabbing: Reports describe localized skin peeling, crusting, or superficial erosions where the patch was applied. These are expected tissue responses to high-fluence laser passes, and the narratives indicate they healed within the normal 7-to-10-day recovery window.
• No Structural Failures: None of the reports describe device malfunctions, chemical burns from the PFD fluid, or long-term scarring directly caused by the patch itself.

Safety Database Context

When reviewing MAUDE data, clinicians must remember that the database relies on voluntary reporting by providers and mandatory reporting by manufacturers when they become aware of an event. MAUDE reports represent passive surveillance; they do not establish the overall incidence of a complication, nor do they prove that the device was the direct cause of the injury. The low absolute number of reports (6 events over more than a decade of use) indicates an exceptionally strong safety profile for the DeScribe Patch.

---

Patient Selection and Fitzpatrick Skin Type Boundaries

While the DeScribe Patch is a valuable clinical tool, patient selection must account for Fitzpatrick Skin Type boundaries to minimize risks of pigmentary complications.

Fitzpatrick Skin Types I-III (The Sweet Spot)

The patch is formally FDA-cleared for patients with Fitzpatrick Skin Types I-III (fair to medium-light skin that burns easily and tans minimally). In these patients, the concentration of epidermal melanin is low, meaning there is minimal competing target for the laser light. The laser energy passes cleanly through the epidermis to reach the dermis, and the risk of post-inflammatory pigmentary changes is low, making them ideal candidates for rapid 4-pass treatments.

Fitzpatrick Skin Types IV-VI (Skin of Color Considerations)

For patients with Fitzpatrick Skin Types IV-VI (darker skin types, including Hispanic, Asian, and Afro-Caribbean skin), the epidermis contains a high concentration of active melanin. Melanin absorbs laser light across all wavelengths, particularly shorter wavelengths like 532 nm and 694 nm.

┌────────────────────────────────────────────────────────────┐
│              Skin of Color (Fitzpatrick IV-VI) Warning     │
├────────────────────────────────────────────────────────────┤
│  High Epidermal Melanin Competes for Laser Energy.         │
│  - Increased risk of Post-Inflammatory Hyperpigmentation.  │
│  - Increased risk of Hypopigmentation (loss of pigment).   │
│  - Multi-pass treatments must be approached with caution,  │
│    using lower fluences and longer pulse widths.           │
└────────────────────────────────────────────────────────────┘

When performing laser tattoo removal on darker skin:

1. Epidermal Heating: The laser energy absorbed by epidermal melanin generates significant heat, increasing the risk of thermal damage to the surrounding tissue.
2. Pigmentary Shifts: The primary risk is post-inflammatory hyperpigmentation (PIH, where the skin darkens) or hypopigmentation (where the skin loses its natural pigment, leaving ghost-like white outlines of the tattoo). Hypopigmentation is often permanent if the melanocytes are destroyed.

While the DeScribe Patch conducts heat away from the skin and provides some thermal protection, performing four laser passes in a single session on a Fitzpatrick Type VI patient remains a high-risk procedure. The cumulative energy delivered can overwhelm the skin's thermal clearance capacity.

Therefore, in skin of color, most experienced laser surgeons recommend a conservative approach:

• Limit treatments to 1 or 2 passes per session, even when using the patch.
• Use longer wavelengths (like 1064 nm), which penetrate deeper and are less absorbed by epidermal melanin.
• Utilize longer pulse widths (picosecond rather than nanosecond) to minimize photoacoustic trauma to surrounding tissue.
• Maximize the interval between treatment sessions (8 to 12 weeks) to allow the skin's inflammatory response to fully subside before re-treating.

---

FAQs

Can the DeScribe Patch be used with both Q-switched and picosecond lasers?

Yes. The FDA expanded the patch's clearance in 2017 to include compatibility with both Q-switched lasers (operating at 532 nm, 694 nm, 755 nm, and 1064 nm) and picosecond lasers (operating at 532 nm, 755 nm, 785 nm, and 1064 nm). It is compatible with major laser platforms in modern clinics.

Does the DeScribe Patch reduce the pain of tattoo removal?

Yes, indirectly. While the laser pulses still feel uncomfortable (often described as a hot rubber band snap), the silicone patch helps conduct excess heat away from the skin. Patients in clinical trials reported lower pain scores and less post-treatment burning sensation when the patch was used compared to treatments performed without it.

How many laser passes can be performed using the PFD Patch?

The patch is cleared and clinically validated for performing up to 4 laser passes in a single treatment session. These passes are performed immediately after one another, as the PFD liquid dissolves the epidermal gas frosting almost instantly.

Are there any adverse events reported for the patch in safety databases?

Yes, but they are rare. The openFDA MAUDE database contains exactly 6 adverse event reports associated with the patch under product code PKO. All 6 events are classified as "Injury" and involve localized, transient complications such as superficial blistering, skin peeling, and redness, reflecting a strong safety profile.

Can the PFD Patch be used on dark skin?

While the patch is officially cleared for Fitzpatrick Skin Types I-III, it can be used on darker skin types (Types IV-VI) under cautious clinical protocols. However, because dark skin contains more melanin, performing multiple laser passes increases the risk of blistering, scarring, and permanent hyper- or hypopigmentation. Providers often limit sessions to 1-2 passes on darker skin.

Does the patch make tattoo removal more expensive?

Yes. The DeScribe Patch is a single-use, medical-grade accessory that adds a direct material cost to each session. Clinics typically charge an additional fee (ranging from $50 to $150 per session) to cover the cost of the patch. However, because the patch enables multiple passes per visit and accelerates clearance, fewer total sessions may be needed, so the overall cost of complete removal can be comparable to or lower than single-pass treatment.

What is the shelf-life of the DeScribe Patch?

Unopened DeScribe Patches should be stored at room temperature and have a manufacturer-designated shelf life, typically printed on the sterile packaging. Because the PFD liquid is volatile, if a patch packaging is compromised or has passed its expiration date, the PFD may have partially evaporated, reducing its optical clearing effectiveness.

Can the patch be cut to fit smaller tattoos?

Yes. Clinicians can cut the silicone patch with sterile surgical scissors to match the specific geometry of a small or irregular tattoo. However, care must be taken to ensure that the cut patch still completely covers the treated zone, with sufficient margins to prevent PFD liquid from leaking out and laser energy from striking unprotected skin.

---

Sources

• FDA. 510(k) Premarket Notification Database: DESCRIBE PFD Patch (K172689). Merz North America, Inc. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K172689
• FDA. 510(k) Premarket Notification Database: DeScribe Transparent PFD Patch (K150212). On Light Sciences, Inc. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cf510k/510k.cfm?id=K150212
• Biesman, B. S., O'Neil, M. P., & Costner, C. (2015). Rapid, high-fluence multi-pass Q-switched laser treatment of tattoos with a transparent perfluorodecalin-infused patch: a pilot study. Lasers in Surgery and Medicine. PubMed 26266835. https://pubmed.ncbi.nlm.nih.gov/26266835/
• Biesman, B. S., & Costner, C. Evaluation of a transparent perfluorodecalin-infused patch as an adjunct to laser-assisted tattoo removal: a pivotal trial. Lasers in Surgery and Medicine. DOI 10.1002/lsm.22659. https://onlinelibrary.wiley.com/doi/abs/10.1002/lsm.22659
• Perfluorodecalin-infused patch in picosecond and Q-switched laser-assisted tattoo removal: safety in Fitzpatrick IV-VI skin types. PubMed 30311666. https://pubmed.ncbi.nlm.nih.gov/30311666/
• FDA MAUDE Database. Adverse event reports for product code PKO (Transparent Patch For Use In Treatment Of Tattoos), June 2026. U.S. Food and Drug Administration.